Sarepta Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $401,251 | $730,803 | $442,934 | $399,356 |
Gross Profit | 251,866 | 611,441 | 44,226 | 248,581 |
EBITDA | 30,168 | 375,481 | -252,199 | -168,034 |
EBIT | 19,759 | 364,887 | -257,452 | -186,484 |
Net Income | -4,890 | 330,959 | -282,847 | -179,947 |
Net Change In Cash | 401,251 | 730,803 | 442,934 | 399,356 |
Free Cash Flow | -8,249 | -205,764 | 125,377 | -42,831 |
Cash | 571,148 | 464,450 | 801,282 | 613,077 |
Basic Shares | 105,431 | 121,916 | 104,793 | 100,237 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,198,237 | $1,901,979 | $1,243,336 | $933,013 |
Gross Profit | 1,316,733 | 1,582,880 | 1,092,993 | 793,024 |
EBITDA | -647,973 | 316,889 | -453,691 | -594,851 |
EBIT | -692,494 | 279,165 | -498,088 | -636,715 |
Net Income | -713,410 | 235,239 | -535,977 | -703,488 |
Net Change In Cash | 2,198,237 | 1,901,979 | 1,243,336 | 933,013 |
Free Cash Flow | -307,451 | -352,743 | -588,338 | -357,597 |
Cash | 801,282 | 1,103,010 | 428,430 | 966,777 |
Basic Shares | 104,793 | 107,875 | 92,398 | 87,559 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.42 |
2026-03-31 | $3.16 |
2025-12-31 | -$3.58 |
2025-09-30 | -$0.13 |